18:13 , Aug 31, 2018 |  BC Week In Review  |  Financial News

ApoGen expands series A to $11M

Drug-resistant cancer company ApoGen Biotechnologies Inc. raised an additional $4 million on Aug. 23 from M Ventures and existing investors in its series A round, bringing the round's total to $11 million. M Ventures is...
21:53 , Aug 17, 2018 |  BioCentury  |  Finance

MD Anderson’s blooms

The recent launch of Magnolia Neurosciences Corp. with a $31 million series A round is the latest example of a broader effort by the University of Texas MD Anderson Cancer Center to ramp up company...
17:25 , Aug 17, 2018 |  BC Week In Review  |  Financial News

MD Anderson launches neuroscience newco with $31M series A

The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners (Seattle, Wash.) have co-founded Magnolia Neurosciences Corp. (New York, N.Y.), which launched Aug. 13 with a $31 million series A round. Eli Lilly...
10:03 , Aug 13, 2018 |  BC Extra  |  Financial News

MD Anderson launches neuroscience newco with $31M series A

The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners (Seattle, Wash.) have co-founded Magnolia Neurosciences Corp. (New York, N.Y.), which launched Monday with a $31 million series A round. Participating in the...
18:56 , Aug 10, 2018 |  BC Week In Review  |  Financial News

Artios raises £65M series B

Artios Pharma Ltd. (Cambridge, U.K.) raised £65 million ($84.3 million) in an oversubscribed, tranched series B round led by new investors Andera Partners and LSP. Fellow new investors Pfizer Ventures and Novartis Venture Fund also...
06:02 , Aug 10, 2018 |  BC Extra  |  Financial News

Artios raises £65M series B

Artios Pharma Ltd. (Cambridge, U.K.) raised £65 million ($84.3 million) in an oversubscribed, tranched series B round led by new investors Andera Partners and LSP. Fellow new investors Pfizer Ventures and Novartis Venture Fund also...
19:59 , Jul 27, 2018 |  BioCentury  |  Finance

Manipulating microglia

Alector Inc.’s $133 million series E round provides enough runway for the immuno-neurology and immuno-oncology company to take at least five programs into the clinic in the next two years. Participants in the untranched round,...
18:11 , Jul 27, 2018 |  BC Week In Review  |  Financial News

Alector raises $133M series E

Immuno-neurology and immuno-oncology company Alector Inc. (South San Francisco, Calif.) raised $133 million in a series E round. Participants included new investors Deerfield Management, Federated Kaufmann Fund, Section 32, Euclidean Capital, Foresite Capital, Lilly Asia Ventures,...
11:02 , Jul 25, 2018 |  BC Extra  |  Financial News

Alector raises $133M series E

Immuno-neurology and immuno-oncology company Alector Inc. (South San Francisco, Calif.) raised $133 million in a series E round. Participants included new investors Deerfield Management, Federated Kaufmann Fund, Section 32, Euclidean Capital, Foresite Capital, Lilly Asia Ventures,...
19:48 , Jun 29, 2018 |  BioCentury  |  Finance

Carisma’s attraction

Macrophage immunotherapy play Carisma Therapeutics Inc. has developed biomarkers that it can use to track macrophage activity and tumor response in preclinical and clinical studies, leading Wellington Partners to join its $53 million series A...